A Philadelphia jury has awarded $8 billion to a plaintiff who says Johnson & Johnson and one of their subsidiaries produced a drug that is linked to the abnormal growth of female breast tissue in boys.
The plaintiff, Nicholas Murray, 26, claims he developed breasts after he was prescribed Risperdal, an anti-psychotic drug prescribed to him after being diagnosed with an autism spectrum disorder.
The plaintiff’s attorneys claimed that Johnson & Johnson prioritized profits over the welfare of its customers by failing to inform them about the potential growth in female breast tissue in boys, a condition known as gynecomastia.
Johnson & Johnson deny the allegations and plan to fight the ruling:
“This decision is inconsistent with multiple determinations outside of Philadelphia regarding the adequacy of the Risperdal labeling, the medicine’s efficacy, and findings in support of the company. We will be immediately moving to set aside this excessive and unfounded verdict.”